Status:
COMPLETED
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Small Intestine Cancer
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Measuring the number of radiolabeled white blood cells in non-Hodgkin's lymphoma tumors may help doctors predict how well patients will respond to treatment, and may help the study of cance...
Detailed Description
OBJECTIVES: * Determine the number of indium In 111-labeled peripheral blood mononuclear cells (PBMCs) and indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into lymphoma tumors ...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed non-Hodgkin's lymphoma
- Indolent or aggressive disease
- Planning to receive a new regimen or starting a regimen of cancer therapy
- At least one tumor lesion measurable in two dimensions as ≥ 1.5 cm by CT scan
- PATIENT CHARACTERISTICS:
- ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
- Life expectancy ≥ 3 months
- No concurrent medical complications that would preclude study compliance
- Not pregnant or nursing
- PRIOR CONCURRENT THERAPY:
- At least 3 weeks since prior chemotherapy (except for nonmyelosuppressive treatments)
- At least 3 weeks since prior radiation therapy
- Concurrent rituximab allowed
Exclusion
Key Trial Info
Start Date :
September 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 10 2012
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00897923
Start Date
September 1 2003
End Date
February 10 2012
Last Update
March 22 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, United States, 52242-1002
2
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905